Literature DB >> 11122849

Biomarkers as surrogates for cancer development.

E Hawk1, J L Viner, J A Lawrence.   

Abstract

Biomarkers are routinely applied in the management of chronic diseases to reduce morbidity and mortality through early diagnosis, as well as to assess the necessity for, and responsiveness to, applied interventions. Biomarkers yield mechanistic insights into layers of biologic organization from molecule to organelle, to cell, and finally to cellular organization and tissue. A step-wise approach to the development of tissue-based biomarkers is presented. These biomarkers may serve as molecular targets for scientific inquiry and intervention, as well as approvable endpoints for clinical trials.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122849     DOI: 10.1007/s11912-000-0074-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  45 in total

Review 1.  Tissue markers of colon cancer risk.

Authors:  D J Ahnen
Journal:  Gastrointest Endosc       Date:  1999-03       Impact factor: 9.427

2.  Validation of proliferation indices as surrogate endpoint biomarkers.

Authors:  D S Alberts; J Einspahr; M Aickin; L Hixson; D Earnest; D Roe; M Powell
Journal:  J Cell Biochem Suppl       Date:  1994

3.  Tamoxifen prevention claim will not be allowed in USA.

Authors:  A Ault
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

Review 4.  Exploring the new world of the genome with DNA microarrays.

Authors:  P O Brown; D Botstein
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

Review 5.  Biomarkers as intermediate end points in chemoprevention trials.

Authors:  S M Lippman; J S Lee; R Lotan; W Hittelman; M J Wargovich; W K Hong
Journal:  J Natl Cancer Inst       Date:  1990-04-04       Impact factor: 13.506

6.  Oral cancer in 57,518 industrial workers of Gujarat, India: a prevalence and followup study.

Authors:  A M Malaovalla; S Silverman; N J Mani; K F Bilimoria; L W Smith
Journal:  Cancer       Date:  1976-04       Impact factor: 6.860

Review 7.  Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.

Authors:  J G Einspahr; D S Alberts; S M Gapstur; R M Bostick; S S Emerson; E W Gerner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-01       Impact factor: 4.254

8.  Ornithine decarboxylase and polyamines in familial adenomatous polyposis.

Authors:  F M Giardiello; S R Hamilton; L M Hylind; V W Yang; P Tamez; R A Casero
Journal:  Cancer Res       Date:  1997-01-15       Impact factor: 12.701

9.  Superficial bladder cancer: progression and recurrence.

Authors:  N M Heney; S Ahmed; M J Flanagan; W Frable; M P Corder; M D Hafermann; I R Hawkins
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

10.  Incidence, survival and mortality in cervical cancer in Norway, 1956-1990.

Authors:  T Bjørge; S O Thoresen; G B Skare
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

View more
  1 in total

1.  Aspirin: still learning about the wonder drug.

Authors:  E T Hawk; J L Viner
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.